Goodbye Viibryd, hello vilazodone. This novel medication has missed the mark in a lot of trials, but it still has a narrow niche in the crowded field of antidepressants.
Twenty years ago, Danny Carlat walked away from industry-funded education and started The Carlat Report. Here he looks back on pivotal moments that have changed the field and shares his perspective on the controversies of today.
This real-world study finds that patients with BPD are able to trade pills for skills, with substantial reductions in a controversial class of medications.
Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of schizophrenia.
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
